EUVIMEDEUVIMED entdecken
Validierungsstudie

External validation of a model informed precision dosing software for cefotaxime for treating critical ill infants and children

Quyen Tu iD, Sainath Raman, Menino Osbert Cotta iD, Luregn Schlapbach, Tavey Dorofaeff, Andras Farkas, Jason A Roberts iD

Journal of Antimicrobial Chemotherapy · 02.07.2026 · 81 (8)

DOI: 10.1093/jac/dkag235 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 27.07.2026. Verfasst von Quyen Tu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Australia. Hauptthemen laut MEDLINE: Cefotaxime, Critical Illness, Anti-Bacterial Agents, Software. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Critically ill infants and children often experience subtherapeutic cefotaxime exposure when administered licenced doses. Dose individualization guided by model informed precision dosing (MIPD) software is emerging, however, external validation of MIPD performance before implementing into clinical practice is necessary. This in silico study assessed the accuracy of an MIPD software in predicting cefotaxime concentrations among critically ill infants and children using the a priori (‘empiric’) and the a posteriori (Bayesian forecasting) approaches.

Methods

The study population was between 1 month and 12 years of age receiving cefotaxime in a paediatric intensive care unit. Essential data was inputted into the MIPD software ID-ODSTM to perform the a priori (4 h and 6 h post dose) and the a posteriori (one- and two-measured serum cefotaxime concentrations) predictions. The concentrations predicted by ID-ODS were compared against measured concentrations, using bias, precision and linear regression methods.

Results

Thirty infants and children with 115 concentration measurements produced 194 simulations for analysis. The median age, weight and serum creatinine concentration were 22.8 months, 10.6 kg and 23 µM/L, respectively. The a priori approach showed high biases, low precisions, and significant underprediction [weighted mean prediction error (WMPE) −48.48%, −85.63%, weighted root mean squared prediction error (WRMSE) 98.86, 87.60% at 4 h and 6 h, respectively]. The a posteriori approach exhibited improved accuracy (WMPE 0.28%, −21.54%, WRMSE 76.41%, 58.98% for one and two samples, respectively). MIPD-guided dose adjustments achieved pre-defined PK-PD targets in >90% of simulations using the a posteriori approach.

Conclusions

MIPD incorporating measured blood samples of cefotaxime increases the likelihood of achieved target drug concentrations in treating severe infections among critically ill infants and children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CefotaximeCritical IllnessAnti-Bacterial AgentsSoftwareHumansInfantChild, PreschoolChildFemaleComputer SimulationMaleIntensive Care Units, PediatricThird Generation CephalosporinsSecond Generation Cephalosporins

Substanzen

CefotaximeAnti-Bacterial AgentsThird Generation CephalosporinsSecond Generation Cephalosporins

Autor:innen und Institutionen

  • Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Australia.
  • Paediatric Intensive Care Unit, Queensland Children's Hospital, Brisbane, Australia.
  • Department of Pharmacy, Queensland Children's Hospital, Brisbane, Australia.
  • Children's Intensive Care Research Program, Child Health Research Centre, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
  • Department of Pediatric and Neonatal Intensive Care, University Children's Hospital Zurich, Zurich, Switzerland.
  • Optimum Dosing Strategies, Bloomingdale, NJ, USA.

ORCID-Profile: Quyen Tu, Menino Osbert Cotta, Jason A Roberts

Zitieren

APA

Tu, Q., Raman, S., Cotta, M. O., Schlapbach, L., Dorofaeff, T., Farkas, A., & Roberts, J. A. (2026). External validation of a model informed precision dosing software for cefotaxime for treating critical ill infants and children. Journal of Antimicrobial Chemotherapy, 81(8). https://doi.org/10.1093/jac/dkag235

Vancouver

Tu Q, Raman S, Cotta MO, Schlapbach L, Dorofaeff T, Farkas A, et al. External validation of a model informed precision dosing software for cefotaxime for treating critical ill infants and children. Journal of Antimicrobial Chemotherapy. 2026;81(8). doi:10.1093/jac/dkag235

BibTeX
@article{Tu2026,
  author = {Tu, Quyen and Raman, Sainath and Cotta, Menino Osbert and Schlapbach, Luregn and Dorofaeff, Tavey and Farkas, Andras and Roberts, Jason A},
  title = {External validation of a model informed precision dosing software for cefotaxime for treating critical ill infants and children},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {8},
  doi = {10.1093/jac/dkag235}
}
Kostenlos starten →